GlycoNex Inc. is a Taiwan-based company principally engaged in the development and licensing of anti-cancer monoclonal antibodies, as well as the provision of carbohydrate antigen and protein drug related commission services. The Company is mainly involved in the development of anti-cancer monoclonal antibody new drugs and bio-similar drugs, as well as the licensing of monoclonal antibody targets and carbohydrate antigen and protein drug related services. The Company distributes its products in domestic market and to overseas markets, such as the rest areas of Asia.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
14/09/26	NT$21.80	0.00%	38,213
11/09/26	NT$21.80	+0.93%	92,506
10/09/26	NT$21.60	0.00%	108,717
09/09/26	NT$21.60	-1.14%	77,031
08/09/26	NT$21.85	-1.35%	106,623

End-of-day quote Taipei Exchange

More quotes

End-of-day quote Taipei Exchange 14/09/2026			5-day change	1st Jan Change
21.80 ^TWD	0.00%		-1.58%	-15.34%

08-13	GlycoNex Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-03	GlycoNex Inc Doses First Patient In Phase I Trial Of GNX1021	CI

Market Cap	2.45B 77.14M 66.84M 63.08M 57.23M 107M 7.39B 108M 753M 290M 3.75B 290M 283M 11.92B	P/E 2024	-11.8x	P/E 2025	-11.9x
Enterprise Value	2.23B 70.23M 60.85M 57.43M 52.1M 97.73M 6.73B 98.44M 686M 264M 3.41B 264M 258M 10.86B	EV / Sales 2024	154x	EV / Sales 2025	67.8x
Free-Float	79.89%	Yield 2024 *	-	Yield 2025	-

08-13	GlycoNex Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-03	GlycoNex Inc Doses First Patient In Phase I Trial Of GNX1021	CI
06-11	Glyconex Announces Positive Topline Results for Phase III Clinical Trial of Denosumab Biosimilar Spd8	CI
05-14	GlycoNex Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-14	GlycoNex, Inc Receives PMDA Approval To Initiate First-In-Human Phase 1 Trial Of GNX1021 In Gastrointestinal Cancers	CI
03-23	GlycoNex Inc. And Nippon Kayaku Co., Ltd. Enters Collaboration To Advance Next-Generation ADC Candidate	CI
03-13	GlycoNex Incorporation Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12-08	GlycoNex Signs CDMO Service Agreement with Change Cure to Advance HMGB1-Targeted Antibody Program	CI
11-24	Glyconex, Inc. and Hokkaido University Hospital Launch Study to Advance Glycan-Directed ADC Development in Gastric Cancer	CI
11-14	GlycoNex Incorporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
29/10/25	GlycoNex announces last patient dosed in phase 3 trial of SPD8, a denosumab biosimilar for osteoporosis	RE
29/10/25	GlycoNex, Inc. Announces Last Patient Dosed in Phase 3 Trial of SPD8, a Denosumab Biosimilar for Osteoporosis	CI
13/08/25	GlycoNex Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI

1 week	-1.58%
Current month	-3.33%
1 month	-4.39%
3 months	-18.66%
6 months	-9.92%
Current year	-15.34%

GlycoNex Incorporation Stock

Stocks

4168

TW0004168000

Biotechnology & Medical Research

Valuation: GlycoNex Incorporation

Chart: GlycoNex Incorporation

Latest news: GlycoNex Incorporation

Press Releases: GlycoNex Incorporation

Quotes and Performance

Price Extremes

Managers and Directors: GlycoNex Incorporation

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

1 week	21.05	22.3
1 month	21.05	23
Current year	21.05	30
1 year	20.55	30
3 years	15.6	31.85
5 years	15.6	46.9
10 years	10.2	46.9

Manager	Title	Age	Since
Mei Chun Yang CEO	Chief Executive Officer	-	01/01/2019
Dih Fen Wu DFI	Director of Finance/CFO	-	01/01/2010
Yao Hua Lue IRC	Investor Relations Contact	-	12/11/2012

Director	Title	Age	Since
Tong Hsuan Chang CHM	Chairman	-	01/02/2001
Kao Chung Tsai BRD	Director/Board Member	64	-
Ling-Chun Tsai BRD	Director/Board Member	-	25/05/2012

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GLYCONEX INCORPORATION	0.00%	-1.58%	-19.85%	-22.70%	77.56M
LONZA GROUP AG	+0.56%	-4.71%	-2.45%	+9.18%	45.48B
REVOLUTION MEDICINES, INC.	+0.66%	-2.34%	+340.62%	+530.14%	43.68B
IQVIA HOLDINGS INC.	+1.49%	-0.78%	+41.90%	+24.75%	43.09B
BEONE MEDICINES AG	+2.11%	-1.24%	+9.09%	+78.25%	39.4B
CELLTRION, INC.	+0.34%	-4.03%	+9.34%	+38.90%	31.91B
ASCENDIS PHARMA A/S	+0.53%	-2.08%	-	-	17.31B
MEDPACE HOLDINGS, INC.	+1.34%	+0.70%	+21.35%	+112.62%	16.4B
EUROFINS SCIENTIFIC SE	+2.07%	+0.78%	+13.07%	+30.91%	14.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.85%	-5.33%	+78.63%	+31.45%	13.28B
Average	+0.72%	-2.20%	+54.63%	+92.61%	26.49B
Weighted average by Cap.	+0.94%	-2.83%	+75.97%	+127.91%

	2024	2025
Net sales	14.7M 462K 401K 378K 343K 643K 44.31M 648K 4.51M 1.74M 22.48M 1.74M 1.7M 71.46M	37.86M 1.19M 1.03M 974K 883K 1.66M 114M 1.67M 11.63M 4.48M 57.89M 4.47M 4.37M 184M
Net income	-230M -7.22M -6.26M -5.91M -5.36M -10.05M -692M -10.13M -70.55M -27.18M -351M -27.13M -26.53M -1.12B	-235M -7.4M -6.41M -6.05M -5.49M -10.29M -709M -10.37M -72.24M -27.84M -360M -27.78M -27.17M -1.14B
Net Debt	-442M -13.9M -12.05M -11.37M -10.31M -19.35M -1.33B -19.49M -136M -52.32M -676M -52.22M -51.07M -2.15B	-220M -6.91M -5.99M -5.65M -5.13M -9.61M -662M -9.68M -67.47M -26M -336M -25.95M -25.38M -1.07B